| Literature DB >> 34104486 |
Amr Hodhod1, Fabiola Oquendo1, Thomas Tablowski1, Ruba Abdul-Hadi1, Walid Shahrour1, Ahmed Kotb1, Owen Prowse1, Hazem Elmansy1.
Abstract
OBJECTIVES: To present the 12-month outcomes of 'Top-Down' holmium laser enucleation of the prostate (HoLEP). PATIENTS AND METHODS: We retrospectively reviewed the charts of prospectively collected patients who underwent Top-Down HoLEP between 2017 and 2018. All cases were operated upon by a single urologist (H.E), using a 100-W holmium:YAG laser with a 550-μm laser fibre. We recorded the enucleation time, morcellation time, intraoperative, and postoperative complications. All patients had postoperative follow-up visits at 1, 3, 6 and 12 months. The evaluation included the International Prostate Symptom Score (IPSS), quality-of-life (QoL) assessment, measurement of maximum urinary flow rate (Qmax) and the post-void residual urine volume (PVR).Entities:
Keywords: Benign prostatic hyperplasia; enucleation; holmium laser
Year: 2020 PMID: 34104486 PMCID: PMC8158276 DOI: 10.1080/2090598X.2020.1805964
Source DB: PubMed Journal: Arab J Urol ISSN: 2090-598X
Figure 1.Important steps of Top-Down HoLEP
Patients’ characteristics and preoperative data
| Characteristic | Value | |
|---|---|---|
| Age, years, median (range) | 72.8 (54–88) | |
| Presentation, | LUTS | 24 (40) |
| Retention | 20 (33.4) | |
| Retention + bladder stones | 6 (10) | |
| Haematuria | 4 (6.7) | |
| Clot retention | 3 (5) | |
| Retention + ARF | 2 (3.3) | |
| LUTS + haematuria | 1 (1.6) | |
| Prostate size, mL, median (range) | 124 (70–266) | |
| Prostate size >100 mL, | 37 (61.7) | |
| Preoperative PSA level, ng/ml, median (range) | 6 (0.84–27.1) | |
| Preoperative IPSS, median (range) | 21 (10–34) | |
| Preoperative QoL, median (range) | 5 (2–6) | |
| Preoperative PVR, mL, median (range) | 400 (11–2600) | |
| Preoperative Qmax, mL/s, median (range) | 8.4 (5.5–15) | |
| Recurrent after TURP, | 16 (26.7) | |
Top-Down postoperative outcome measures at 1, 3, 6, and 12 months
| Variable | Value | |
|---|---|---|
| Number of patients | ||
| IPSS, median (range) | 0.045 | |
| QoL, median (range) | 0.04 | |
| PVR, median (range) | 0.12 | |
| Qmax, mL/s, median (range) | 0.17 | |
| PSA level, ng/mL, median (range) | <0.001 |
Comparison among learning curve groups in relation to the operative and postoperative outcomes
| Variable | First 20 cases | Second 20 cases | Last 20 cases | |
|---|---|---|---|---|
| Enucleation time, min, median (range) | 91 (50–130) | 86 (25–184) | 67 (45–200) | 0.56 |
| Resected weight, g, median (range) | 95 (27–190) | 81 (44–236) | 86 (34–242) | 0.76 |
| Enucleation efficiency, g/min, median (range) | 0.86 (0.4–1.34) | 0.9 (0.42–1.9) | 0.91 (0.63–3.7) | 0.99 |
| SUI, | 1 (5) | 2 (10) | 0 | 0.35 |
| 12-month % IPSS improvement, median (range) | 81.25 (72.7–93.3) | 82.54 (42.2–100) | 82.35 (60–100) | 0.98 |
| 12-month % QoL improvement, median (range) | 80 (50–100) | 81.7 (33.3–100) | 85.5 (66.7–100) | 0.58 |
| 12-month % PVR improvement, median (range) | 93.3 (36.1–100) | 90.86 (58.3–100) | 100 (43.8–100) | 0.28 |
| 12-month % Qmax improvement, median (range) | 170.3 (100–198.2) | 200.4 (103–436.5) | 235.3 (110–648) | 0.2 |